Pfizer lost more than $2 billion in the third quarter as an expected COVID-19 product sales decline clipped revenue.
Sales of the drugmaker's COVID treatment Paxlovid and the vaccine Comirnaty slid 97% and 70%, respectively, as Pfizer, like its competitors, switched to selling on the commercial market instead of to governments. ....
Pfizer lost more than $2 billion in the third quarter as an expected COVID-19 product sales decline clipped revenue.
Sales of the drugmaker's COVID treatment Paxlovid and the vaccine Comirnaty slid 97% and 70%, respectively, as Pfizer, like its competitors, switched to selling on the commercial market instead of to governments. ....
Pfizer lost more than $2 billion in the third quarter as an expected COVID-19 product sales decline clipped revenue.
Sales of the drugmaker's COVID treatment Paxlovid and the vaccine Comirnaty slid 97% and 70%, respectively, as Pfizer, like its competitors, switched to selling on the commercial market instead of to governments. ....
https://www.dailymail.co.uk/wires/ap/article-12692849/A-continuing-decline-sales-COVID-19-products-clips-revenue-Pfizer.html